查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
转甲状腺素蛋白淀粉样变性治疗市场规模、份额和趋势分析报告：按类型（ATTR-PN、ATTR-CM）、疗法、疾病类型、分销渠道、地区分部预测2022-2030
市场调查报告书
商品编码
1133367

转甲状腺素蛋白淀粉样变性治疗市场规模、份额和趋势分析报告：按类型（ATTR-PN、ATTR-CM）、疗法、疾病类型、分销渠道、地区分部预测2022-2030

Transthyretin Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Type (ATTR-PN, ATTR-CM), By Therapy, By Disease Type, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

转甲状腺素蛋白淀粉样变性治疗市场增长和趋势

根据 Grand View Research, Inc. 的新报告，转甲状腺素蛋白淀粉样变性治疗的全球市场规模将从 2022 年到 2030 年以 7.6% 的复合年增长率扩大，到 2030 年达到 91.7 亿美元。转甲状腺素蛋白淀粉样变性治疗市场主要是由支持性报销计划的存在和不断增长的非洲裔美国人推动的。由于其对 ATTR 淀粉样变性的易感性增加，不断增长的非裔美国人人口在整个期间促进了行业增长。Val122Ile 是全球最常见的突变，可导致 65 岁以上人群发生心肌病。此外，这种 Val122Ile 突变存在于 3% 至 4% 的全球非裔美国人人口中。

为开发新的诊断技术和多模式治疗方法而增加的研究工作有望提高转甲状腺素蛋白淀粉样变性的生存率和预后。例如，2019 年 11 月，淀粉样变性研究联盟开发了一种疾病特异性患者报告结果 (PRO) 工具，以从患者的角度了解和衡量转甲状腺素蛋白淀粉样变性的影响。此类工具的引入将支持新的靶向特异性药物开发研究，并通过了解疾病的复杂性和患者需求来扩大转甲状腺素蛋白淀粉样变性治疗市场的机会。

主要参与者采取的战略举措，例如提高对 ATTR 等靶向疾病的认识以及可用治疗的长期益处，预计将推动行业增长。例如，2019 年Pfizer, Inc.与世界心臟联合会合作，发起了“心臟英雄”活动。在此次活动中，Pfizer, Inc.为患者和医生提供与 ATTR-CM 相关的教育信息和资源。预计此类活动将提高这种疾病的早期诊断和治疗率。

此外，作为企业社会责任活动的一部分，主要公司提供免费药品的行动也有望推动市场增长。例如，Pfizer, Inc.的患者援助计划为符合条件的患者免费提供Pfizer, Inc.药品，例如 VYNDAMAX。被诊断患有淀粉样变性的人可以通过在 Vandalink 平台上註册来利用这些程序。预计此类计划将鼓励医生开具 TAGRISSO 作为转甲状腺素蛋白淀粉样变性患者的药物治疗。

转甲状腺素蛋白淀粉样变性治疗市场报告亮点

按类型划分，由于这种疾病的高流行率和老年人口的增加，ATTR-CM 将在 2021 年占据主要份额。ATTR-PN 预计将在整个预测期内表现出最快的增长率。这部分的增长是由于存在强大的管道。

从治疗方法来看，靶向治疗领域将在 2021 年占据压倒性的份额，因为它在全球范围内被批准为 ATTR-CM 的治疗方法，并且处方率正在上升。

按疾病类型，遗传性转甲状腺素蛋白淀粉样变性部分在 2021 年占据市场主导地位，原因是管道增长和製药公司之间增加的药物开发战略联盟。

从销售渠道来看，随着越来越多的医院致力于诊断、研究和治疗转甲状腺素蛋白淀粉样变性，医院药房将在 2021 年占据最大份额。

由于新药处方的增加、充足的报销政策和高治疗率，北美地区在 2021 年占最大份额。

预计 MEA 地区将在预测期内呈现最快的增长率。该地区的增长归因于 ATTR 淀粉样变性发病率的上升。

报告概述目录细分方法索取免费样品副本

目录

第一章执行摘要

  • 市场快照
  • 竞争环境
  • 分部展望

第二章研究方法论

  • 信息采购
  • 信息或数据分析
  • 市场製定和验证

3. 转甲状腺素蛋白淀粉样变性治疗市场变量、趋势和范围

  • 母市场分析
  • 市场动态
    • 市场驱动力分析
      • 发病率增加
      • 老年人口不断增长
      • 强大的 ATTR 药物疗法管道
      • 疾病意识的增强
    • 市场约束分析
      • 疾病误诊
      • 治疗费用高

4 转甲状腺素蛋白淀粉样变性治疗市场：细分分析，按类型，2018-2030 年（百万美元）

  • 定义和范围
  • 2018-2030 年按类型分列的全球转甲状腺素蛋白淀粉样变性治疗市场（百万美元）
  • 市场规模和预测，趋势分析，2018-2030（百万美元）
    • ATTR-PN
    • ATTR-CM

5. 转甲状腺素蛋白淀粉样变性治疗市场：细分分析，按治疗，2018-2030 年（百万美元）

  • 定义和范围
  • 全球转甲状腺素蛋白淀粉样变性治疗市场，按治疗，2018-2030 年（百万美元）
    • 靶向治疗
    • 支持性护理
    • 管道疗法

6.转甲状腺素蛋白淀粉样变性治疗市场：细分分析，按疾病类型，2018-2030 年（百万美元）

  • 定义和范围
  • 全球转甲状腺素蛋白淀粉样变性治疗市场，按疾病类型，2018-2030 年（百万美元）
  • 市场规模和预测，趋势分析，2018-2030（百万美元）
    • 遗传性转甲状腺素蛋白淀粉样变性
      • 多发性神经病
      • 心肌病
      • 混合型
    • 野生型淀粉样变性

7.转甲状腺素蛋白淀粉样变性治疗市场：细分分析，按分销渠道，2018-2030（百万美元）

  • 定义和范围
  • 2018-2030年全球转甲状腺素蛋白淀粉样变性疗法市场，按分销渠道（百万美元）
  • 市场规模和预测，趋势分析，2018-2030（百万美元）
    • 医院药房
    • 专业药房
    • 零售药店
    • 网上药店

8.转甲状腺素蛋白淀粉样变性治疗市场：区域市场分析，2018-2030（百万美元）

  • 定义和范围
  • 2021 年和 2030 年区域市场份额分析
  • 区域市场仪表板
  • 区域市场：主要参与者
  • 2021-2030 年市场规模、预测和趋势分析：
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 俄罗斯
  • 亚太地区
    • 日本
    • 澳大利亚
    • 印度
    • 中国
    • 新加坡
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国

第 9 章 竞争格局

  • 战略框架
  • 市场参与的分类
  • 公司简介
    • Pfizer Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Johnson & Johnson Services, Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Ionis Pharmaceuticales, Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Alnylam Pharmaceuticals, Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • BridgeBio Pharma, Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Bristol-Myers Squibb Company
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Acrotech Biopharma
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Astrazeneca
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Astellas Pharma, Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Prothena
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • SOM Biotech
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
Product Code: GVR-4-68039-977-9

Transthyretin Amyloidosis Treatment Market Growth & Trends:

The global transthyretin amyloidosis treatment market size is expected to reach USD 9.17 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 7.6% from 2022 to 2030. The transthyretin amyloidosis treatment market is mainly driven by the presence of supportive reimbursement programs and the growing African American population. The increasing African American population acted as a catalyst for the industry growth throughout the period owing to the high susceptibility to ATTR amyloidosis. The Val122Ile is the most prevalent mutation worldwide that leads to cardiomyopathy among the population specific to aged 65 years and above. Furthermore, this Val122Ile mutation is present in 3% to 4% of the African American population worldwide.

An increase in research activities for the development of novel diagnostic techniques and multidisciplinary therapeutic approaches is expected to lead to an increased survival rate and a more favorable prognosis of transthyretin amyloidosis. For instance, in November 2019, the Amyloidosis Research Consortium developed a disease-specific patient-reported outcome (PRO) tool to understand and measure the impact of transthyretin amyloidosis from the patient perspective. An introduction of such a tool will boost the research in developing a new target-specific drug by understanding disease complexity and patients' need, thereby widening the opportunity in the transthyretin amyloidosis treatment market.

Strategic initiatives undertaken by major players such as creating awareness regarding the target conditions such as ATTR and the long-term benefits of available therapies are expected to fuel industry growth. For instance, in 2019, Pfizer, Inc., in collaboration with the World Heart Federation, started the "Heart Hero" campaign. Under this campaign, Pfizer, Inc. provides educational information and resources related to ATTR-CM to patients and physicians. Such campaigns are expected to boost the early diagnosis of the disease and increase the treatment rate over time.

The movement undertaken by key players to provide free-of-cost medicine under their CSR activities is also projected to fuel market growth. For instance, the Pfizer Patient Assistance Program provides Pfizer medicines such as VYNDAMAX free of cost to eligible patients. People diagnosed with amyloidosis can take advantage of such programs by enrolling at the Vandalink platform. Such programs are expected to encourage physicians to prescribe this drug to a patient as drug therapy in transthyretin amyloidosis patients.

Transthyretin Amyloidosis Treatment Market Report Highlights:

  • By type, the ATTR-CM accounted for a leading share in 2021 owing to the high prevalence of the disease and the rising geriatric population. The ATTR-PN is expected to exhibit the fastest growth rate throughout the forecast period. The segment growth is attributed to the presence of a strong pipeline
  • By therapy, the targeted therapy segment grabbed a dominant share in 2021 owing to the worldwide approval of the therapies and the growing prescription rate for the treatment of ATTR-CM
  • By disease type, the hereditary transthyretin amyloidosis segment dominated the market in 2021 owing to growing strategic alliances among various pharmaceutical companies aiming toward drug development along with growing pipeline drugs
  • By distribution channel, the hospital pharmacies captured the largest share in 2021 as most of the hospitals are working toward the diagnosis, research, and treatment of transthyretin amyloidosis
  • North America region held the largest share in 2021 owing to the increasing novel drug prescription, proper reimbursement policies, and higher treatment rates in the region
  • The MEA region is expected to exhibit the fastest growth rate throughout the forecast period. The segment growth is attributed to the increasing incidence of ATTR amyloidosis

Report SummaryTable of ContentsSegmentationMethodologyRequest a FREE Sample Copy

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Competition Milieu
  • 1.3. Segment Outlook

Chapter 2. Research Methodology

  • 2.1. Information Procurement
  • 2.2. Information or Data Analysis
  • 2.3. Market Formulation & Validation

Chapter 3. Transthyretin Amyloidosis Treatment Market Variables, Trends & Scope

  • 3.1. Parent Market Analysis
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing incidences of diseases
      • 3.2.1.2. Increasing geriatric population
      • 3.2.1.3. Robust pipeline of ATTR drug therapies
      • 3.2.1.4. Rising awareness about diseases
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Misdiagnosis of the disease
      • 3.2.2.2. High cost of treatment

Chapter 4. Transthyretin Amyloidosis Treatment Market: Segment Analysis, By Type, 2018 - 2030 (USD Million)

  • 4.1. Definitions & Scope
  • 4.2. Global Transthyretin Amyloidosis Treatment Market, By Type, 2018 - 2030 (USD Million)
  • 4.3. Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
    • 4.3.1. ATTR-PN
      • 4.3.1.1. Global Transthyretin Amyloidosis Treatment Market, ATTR-PN, 2018 - 2030 (USD Million)
    • 4.3.2. ATTR-CM
      • 4.3.2.1. Global Transthyretin Amyloidosis Treatment Market, ATTR-CM, 2018 - 2030 (USD Million)

Chapter 5. Transthyretin Amyloidosis Treatment Market: Segment Analysis, By Therapy, 2018 - 2030 (USD Million)

  • 5.1. Definitions & Scope
  • 5.2. Global Transthyretin Amyloidosis Treatment Market, By Therapy, 2018 - 2030 (USD Million)
  • 5.3. Market Size & Forecasts and Trend Analyses, 2018 - 2030
    • 5.3.1. Targeted Therapy
      • 5.3.1.1. Global Transthyretin Amyloidosis Treatment Market, Targeted Therapy, 2018 - 2030 (USD Million)
    • 5.3.2. Supportive Therapy
      • 5.3.2.1. Global Transthyretin Amyloidosis Treatment Market, Supportive Therapy, 2018 - 2030 (USD Million)
    • 5.3.3. Pipeline Therapy
      • 5.3.3.1. Global Transthyretin Amyloidosis Treatment Market, Pipeline Therapy, 2018 - 2030 (USD Million)

Chapter 6. Transthyretin Amyloidosis Treatment Market: Segment Analysis, By Disease Type, 2018 - 2030 (USD Million)

  • 6.1. Definitions & Scope
  • 6.2. Global Transthyretin Amyloidosis Treatment Market, By Disease Type, 2018 - 2030 (USD Million)
  • 6.3. Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
    • 6.3.1. Hereditary Transthyretin Amyloidosis
      • 6.3.1.1. Global Transthyretin Amyloidosis Treatment Market, Hereditary Transthyretin Amyloidosis Treatment Market , 2018 - 2030 (USD Million)
      • 6.3.1.2. Polyneuropathy
      • 6.3.1.2.1. Global Transthyretin Amyloidosis Treatment Market , Polyneuropathy Market, 2018 - 2030 (USD Million)
      • 6.3.1.3. Cardiomyopathy
      • 6.3.1.3.1. Global Transthyretin Amyloidosis Treatment Market, Cardiomyopathy Market, 2018 - 2030 (USD Million)
      • 6.3.1.4. Mixed Type
      • 6.3.1.4.1. Global Transthyretin Amyloidosis Treatment Market, Mixed Type Market, 2018 - 2030 (USD Million)
    • 6.3.2. Wild Type Amyloidosis
      • 6.3.2.1. Global Transthyretin Amyloidosis Treatment Market, Wild Type Amyloidosis Market, 2018 - 2030 (USD Million)

Chapter 7. Transthyretin Amyloidosis Treatment Market: Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)

  • 7.1. Definitions & Scope
  • 7.2. Global Transthyretin Amyloidosis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • 7.3. Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
    • 7.3.1. Hospital Pharmacies
      • 7.3.1.1. Global Transthyretin Amyloidosis Treatment Market, Hospital Pharmacies, 2018 - 2030 (USD Million)
    • 7.3.2. Specialty Pharmacies
      • 7.3.2.1. Global Transthyretin Amyloidosis Treatment Market, Specialty Pharmacies, 2018 - 2030 (USD Million)
    • 7.3.3. Retail Pharmacies
      • 7.3.3.1. Global Transthyretin Amyloidosis Treatment Market, Retail Pharmacies, 2018 - 2030 (USD Million)
    • 7.3.4. Online Pharmacies
      • 7.3.4.1. Global Transthyretin Amyloidosis Treatment Market, Online Pharmacies, 2018 - 2030 (USD Million)

Chapter 8. Transthyretin Amyloidosis Treatment Market: Regional Market Analysis, By Region, 2018 - 2030 (USD Million)

  • 8.1. Definitions & Scope
  • 8.2. Regional Market Share Analysis, 2021&2030
  • 8.3. Regional Market Dashboard
  • 8.4. Regional Market: Key Players
  • 8.5. Market Size, & Forecasts, and Trend Analysis, 2021 to 2030:
  • 8.6. North America
    • 8.6.1. North America market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.6.2. U.S.
      • 8.6.2.1. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.6.3. Canada
      • 8.6.3.1. Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.7. Europe
    • 8.7.1. Europe market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.2. Germany
      • 8.7.2.1. Germany market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.3. U.K.
      • 8.7.3.1. U.K. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.4. France
      • 8.7.4.1. France market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.5. Italy
      • 8.7.5.1. Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.6. Spain
      • 8.7.6.1. Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.7. Russia
      • 8.7.7.1. Russia market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.8. Asia Pacific
    • 8.8.1. Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.8.2. Japan
      • 8.8.2.1. Japan market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.8.3. Australia
      • 8.8.3.1. Australia market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.8.4. India
      • 8.8.4.1. India market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.8.5. China
      • 8.8.5.1. China market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.8.6. Singapore
      • 8.8.6.1. Singapore market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.9. Latin America
    • 8.9.1. Latin America market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.9.2. Mexico
      • 8.9.2.1. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.9.3. Brazil
      • 8.9.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.9.4. Argentina
      • 8.9.4.1. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.10. Middle East & Africa
    • 8.10.1. Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.10.2. South Africa
      • 8.10.2.1. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.10.3. Saudi Arabia
      • 8.10.3.1. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.10.4. UAE
      • 8.10.4.1. UAE market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Strategy Framework
  • 9.2. Market Participation Categorization
  • 9.3. Company Profile
    • 9.3.1. Pfizer Inc.
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Johnson & Johnson Services, Inc.
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Ionis Pharmaceuticales, Inc.
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Alnylam Pharmaceuticals, Inc.
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. BridgeBio Pharma, Inc.
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Bristol-Myers Squibb Company
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Acrotech Biopharma
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Astrazeneca
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Astellas Pharma, Inc.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Prothena
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Product Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. SOM Biotech
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Financial Performance
      • 9.3.11.3. Product Benchmarking
      • 9.3.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of Tables
  • Table 2 List of Secondary Sources
  • Table 3 List of Abbreviations
  • Table 4 Global Transthyretin Amyloidosis Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 5 Global Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 6 Global Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 7 Global Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 8 Global Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 9 Global Transthyretin Amyloidosis Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 10 North America Transthyretin Amyloidosis Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 11 North America Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 12 North America Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 13 North America Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 14 North America Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 U.S. Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 16 U.S. Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 17 U.S. Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 18 U.S. Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Canada Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 20 Canada Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 21 Canada Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 22 Canada Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Europe Transthyretin Amyloidosis Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 24 Europe Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 25 Europe Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 26 Europe Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 27 Europe Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Germany Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 29 Germany Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 30 Germany Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 31 Germany Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 U.K. Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 33 U.K. Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 34 U.K. Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 35 U.K. Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 France Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 37 France Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 38 France Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 39 France Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Italy Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 41 Italy Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 42 Italy Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 43 Italy Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Spain Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 45 Spain Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 46 Spain Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 47 Spain Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Transthyretin Amyloidosis Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 China Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 54 China Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 55 China Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 56 China Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 Japan Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 58 Japan Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 59 Japan Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 60 Japan Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 India Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 62 India Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 63 India Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 64 India Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Australia Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 66 Australia Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 67 Australia Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 68 Australia Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Singapore Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 70 Singapore Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 71 Singapore Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 72 Singapore Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Latin America Transthyretin Amyloidosis Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 74 Latin America Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 75 Latin America Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 76 Latin America Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 77 Latin America Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 78 Brazil Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 79 Brazil Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 80 Brazil Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 81 Brazil Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 82 Mexico Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 83 Mexico Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 84 Mexico Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 85 Mexico Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Argentina Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 87 Argentina Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 88 Argentina Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 89 Argentina Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 90 Middle East & Africa Transthyretin Amyloidosis Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 91 Middle East & Africa Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 92 Middle East & Africa Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 93 Middle East & Africa Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 94 Middle East & Africa Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 95 South Africa Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 96 South Africa Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 97 South Africa Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 98 South Africa Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 99 Saudi Arabia Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 100 Saudi Arabia Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 101 Saudi Arabia Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 102 Saudi Arabia Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 103 UAE Transthyretin Amyloidosis Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 104 UAE Transthyretin Amyloidosis Treatment Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 105 UAE Transthyretin Amyloidosis Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 106 UAE Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Figure 1 Market research process
  • Figure 2 Information procurement
  • Figure 3 Primary research pattern
  • Figure 4 Market research approaches
  • Figure 5 Value chain-based sizing & forecasting
  • Figure 6 Market formulation & validation
  • Figure 7 Transthyretin amyloidosis market segmentation
  • Figure 8 Market driver relevance analysis (Current & future impact)
  • Figure 9 Market restraint relevance analysis (Current & future impact)
  • Figure 10 Market challenge relevance analysis (Current & future impact)
  • Figure 11 Penetration & growth prospect mapping
  • Figure 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Figure 13 Porter's five forces analysis
  • Figure 14 Market penetration vs growth prospect mapping
  • Figure 15 Transthyretin Amyloidosis Treatment Market: Type Movement Analysis
  • Figure 16 ATTR-PN Market, 2018 - 2030 (USD Million)
  • Figure 17 ATTR-CM Market, 2018 - 2030 (USD Million)
  • Figure 18 Transthyretin Amyloidosis Treatment Market: Therapy Movement Analysis
  • Figure 19 Targeted Therapy Market, 2018 - 2030 (USD Million)
  • Figure 20 Supportive Therapy Market, 2018 - 2030 (USD Million)
  • Figure 21 Pipeline Therapy Market, 2018 - 2030 (USD Million)
  • Figure 22 Transthyretin Amyloidosis Treatment Market: Disease Type Movement Analysis
  • Figure 23 Hereditary Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 24 Wild Type Amyloidosis Market, 2018 - 2030 (USD Million)
  • Figure 25 Transthyretin Amyloidosis Treatment Market: Distribution Channel Movement Analysis
  • Figure 26 Hospital Pharmacies Amyloidosis Market, 2018 - 2030 (USD Million)
  • Figure 27 Specialty Pharmacies Amyloidosis Market, 2018 - 2030 (USD Million)
  • Figure 28 Retail Pharmacies Amyloidosis Market, 2018 - 2030 (USD Million)
  • Figure 29 Online Pharmacies Amyloidosis Market, 2018 - 2030 (USD Million)
  • Figure 30 Regional marketplace: Key takeaways
  • Figure 31 Regional outlook, 2021 & 2030
  • Figure 32 North America Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 33 U.S. Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 34 Canada Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 35 Europe Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 36 U.K. Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 37 Germany Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 38 Italy Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 39 Spain Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 40 France Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 41 Russia Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 42 Asia Pacific Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 43 Japan Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 44 Australia Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 45 China Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 46 India Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 47 Singapore Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 48 Latin America Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 49 Brazil Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 50 Mexico Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 51 Argentina Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 52 MEA Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 53 South Africa Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 54 Saudi Arabia Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)
  • Figure 55 UAE Transthyretin Amyloidosis Treatment Market, 2018 - 2030 (USD Million)